Steven P Balk - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Steven P Balk

Showing results (161-170 of 189) with videos related to

Pageof 19

Sort By:

Cancer Research|June 21, 2018

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic AlterationsAdam G Sowalsky, Huihui Ye, Manoj Bhasin, et al.

Molecular Cancer Research : MCR|January 27, 2022

Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical ImplicationsXin Dong, Hui Xue, Fan Mo, et al.

Cell Reports|December 22, 2024

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.

JCO Precision Oncology|September 19, 2019

Low Abundance of Circulating Tumor DNA in Localized Prostate CancerS Thomas Hennigan, Shana Y Trostel, Nicholas T Terrigino, et al.

The Journal of Clinical Investigation|October 19, 2018

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.

Cell Reports|September 8, 2021

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.

Cancer|March 25, 2022

Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancerAdrianna A Mendes, Jiayun Lu, Harsimar B Kaur, et al.

British Journal of Cancer|August 8, 2024

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancerRazia Rahman, Muhammed H Rahaman, Adrienne R Hanson, et al.

Science (New York, N.Y.)|December 15, 2012

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independentKexin Xu, Zhenhua Jeremy Wu, Anna C Groner, et al.

British Journal of Cancer|October 25, 2024

Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancerRazia Rahman, Muhammed H Rahaman, Adrienne R Hanson, et al.

Pageof 19

Search research articles

Showing results (161-170 of 189) with videos related to

Sort By:

Pageof 19

Cancer Research|June 21, 2018

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic AlterationsAdam G Sowalsky, Huihui Ye, Manoj Bhasin, et al.

Molecular Cancer Research : MCR|January 27, 2022

Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical ImplicationsXin Dong, Hui Xue, Fan Mo, et al.

Cell Reports|December 22, 2024

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.

JCO Precision Oncology|September 19, 2019

Low Abundance of Circulating Tumor DNA in Localized Prostate CancerS Thomas Hennigan, Shana Y Trostel, Nicholas T Terrigino, et al.

The Journal of Clinical Investigation|October 19, 2018

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.

Cell Reports|September 8, 2021

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.

Cancer|March 25, 2022

Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancerAdrianna A Mendes, Jiayun Lu, Harsimar B Kaur, et al.

British Journal of Cancer|August 8, 2024

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancerRazia Rahman, Muhammed H Rahaman, Adrienne R Hanson, et al.

Science (New York, N.Y.)|December 15, 2012

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independentKexin Xu, Zhenhua Jeremy Wu, Anna C Groner, et al.

British Journal of Cancer|October 25, 2024

Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancerRazia Rahman, Muhammed H Rahaman, Adrienne R Hanson, et al.

Pageof 19